AI assistant
Sending…
STEPAN CO — Director's Dealing 2017
Feb 23, 2017
32175_dirs_2017-02-23_50b04a90-4c28-4820-abc7-ec132513b24f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: STEPAN CO (SCL)
CIK: 0000094049
Period of Report: 2017-02-21
Reporting Person: PACHOLEC FRANK (Vice President R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-21 | Common Stock | M | 1015 | — | Acquired | 52669.931 | Direct |
| 2017-02-23 | Common Stock | A | 102.495 | $78.91 | Acquired | 2038.28 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-21 | Stock Option (Right to Buy) | $78.58 | A | 1393 | Acquired | 2027-02-20 | Common Stock (1393) | Direct |
| 2017-02-21 | Stock Appreciation Right | $78.58 | A | 4178 | Acquired | 2027-02-20 | Common Stock (4178) | Direct |
| 2017-02-21 | Performance Shares | $ | A | 1120 | Acquired | Common Stock (1120) | Direct | |
| 2017-02-21 | Performance Shares | $ | M | 1131 | Disposed | Common Stock (1131) | Direct |
Footnotes
F1: Amount reported reflects vesting of 1,015 performance shares as shown on Table II due to achievement of certain financial targets by December 31, 2016.
F2: Vests ratably over three years beginning on the date shown.
F3: Each performance share represents a contingent right to receive 1 share of Stepan Company Common Stock. The performance shares vest upon Stepan Company achieving certain financial targets by December 31, 2019.
F4: The performance shares vested upon Stepan Company achieving certain financial targets by December 31, 2016.
More from STEPAN CO
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 25
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 23
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 19